Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development of oncology and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for metastatic breast cancer, gastric cancer, tenosynovial giant cell tumor, hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, and IV iron therapy.

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.